Human Psychopharmacology
Clinical and Experimental

EDITOR-IN-CHIEF
Dr J Guy Edwards
Department of Psychiatry, Royal South Hants Hospital, Southampton SO9 4PE, UK.
Tel: 0703 634288 (Office)

EDITOR FOR NORTH AMERICA **Dr Thomas Roth**
Sleep Disorders and Research Center, Henry Ford Hospital, 2921 West Grand Boulevard, Detroit, Michigan 48202-2689, USA.
Tel: 313 972 1804

EDITORS

Professor Ian Hindmarch
Human Psychopharmacology Research Unit, Robens Institute, University of Surrey, Guildford GU2 5XH, UK

Dr Michael R Trimble
The National Hospitals for Nervous Diseases, Queen Square, London WC1N 3BG, UK

Dr Guy M Goodwin
MRC Brain Metabolism Unit, Royal Edinburgh Hospital, Morningside Park, Edinburgh EH10 5HF, UK

Professor Brian E Leonard
Pharmacology Department, University College, Galway, Republic of Ireland

AIMS AND SCOPE

Human Psychopharmacology aims to communicate the results of clinical and experimental studies relevant to the understanding of new and established psychotropic drugs. To this end the journal publishes articles on the following topics:

- ★ Experimental human psychopharmacology
- ★ Efficacy studies in humans, especially large-scale and placebo controlled trials
- ★ Volunteer studies
- ★ Relevant animal studies
- ★ Effects of psychotropic drugs on physiological systems, including unwanted effects
- ★ Psychotropic drug use and dependence
- ★ Broader ethical psychological and sociological aspects of drug use, misuse and abuse

The content of *Human Psychopharmacology* comprises *Original articles, Short communications* (not exceeding 1500 words). *Reviews* and *Comments* by leading authorities with discussion by other experts, papers on *Practical therapeutics*, report of *International meetings, Book reviews, Correspondence* and *Diary*.

EDITORIAL POLICY

The Editors' policy is to encourage and publish contributions on all aspects of human psychopharmacology. *Human Psychopharmacology* is a multidisciplinary journal and articles dealing with the broader aspects of pharmacotherapy in a social and clinical setting are welcomed. All original articles and short communications are strictly refereed and only studies meeting acceptable ethical standards governing experimentation on animals and man will be considered. Proceedings of meetings and symposia that meet strict editorial criteria may be published as supplements to the journal.
Human Psychopharmacology aims to publish contributions within three to six months of final acceptance.

EDITORIAL ADVISORY BOARD

M. Ackenheil
Munich, Germany
J. Angst
Zurich, Switzerland
R. J. Baldessarini
Belmont, USA
R. H. Belmaker
Beer Sheva, Israel
N. Brunello
Milan, Italy
G. D. Burrows
Victoria, Australia
A. Carlsson
Goteborg, Sweden
S. J. Cooper
Birmingham, UK
J. F. W. Deakin
Manchester, UK
S. E. File
London, UK
D. Healy
Denbigh, Wales
S. R. Hirsch
London, UK
L. E. Hollister
Houston, Texas, USA
K. Inanaga
Kurume, Japan
W. Koslowski
Warsaw, Poland
J. J. Lopez-Ibor, Jr
Madrid, Spain
J. Maj
Krakow, Poland
D. J. Nutt
Bristol, UK
T. Okuma
Tokyo, Japan
T. Ott
Berlin, Germany
A. Puech
Paris, France
R. Rimón
Helsinki, Finland
M. Roth
Cambridge, UK
B. Saletu
Vienna, Austria
M. Schou
Risskov, Denmark
E. M. Sellers
Toronto, Canada
G. Sedvall
Stockholm, Sweden
F. Sulser
Tennessee, USA
C. Thompson
Southampton, UK
P. Turner
London, UK
P. J. Tyrer
London, UK
H. M. van Praag
New York, USA
M. E. Vartanian
Zagorodnoje, Russia
D. Wheatley
Surrey, UK

COPYING OF ARTICLES

The code and the copyright notice appearing at the bottom of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be made for personal or internal use, or for the personal or internal use of specific clients, on the condition that the copier pay for copying beyond that permitted by Sections 107 or 108 of the U.S. Copyright Law. The per-copy fee for each article appears after the dollar sign, and is to be paid through the Copyright Clearance Center Inc. The consent does not extend to other kinds of copying such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Such permission requests, or other inquiries, should be addressed to the publisher.

CONTENTS

Volume 6, Issue Nos 1–4, plus Supplement

HUMAN PSYCHOPHARMACOLOGY

Issue No. 1 March 1991

Acknowledgement ii

Review

Performance Tests in Human Psychopharmacology (1): Test Reliability and Standardization: **A. C. Parrott** 1

Original Articles

Plasma MHPG and AMDP Depression Relations, Evolution and Drug Effect in a Follow-up Study of Depressed Patients: **F. Karege, Ph. Bovier, J.-M. Gaillard and R. Tissot** 11

TSH responsiveness to TRH ('The TRH Test')—of no Diagnostic Value in Depression: **J. A. Vaughan, B. P. O'Malley, S. Barker, K. L. Woods, R. L. Palmer and F. D. Rosenthal** 19

Dopamine Depletion Hypothesis of Cocaine Dependence: A Test: **K. Gill, H. K Gillespie, L. E. Hollister, C. M. Davis and C. A. Peabody** 25

Is Viloxazine an Antidepressant? A Placebo-controlled Double-blind Study in Major Depressive Disorder Presenting in a General Hospital: **C. Thompson and G. Isaacs** 31

Effect of Clonazepam on Tardive Akathisia: **M. Kuniyoshi, K. Ariyawa, C. Miura and K. Inanaga** 39

Urinary Phenylethylamine Excretion in Phobic and Obsessive Patients: **N. Theofilopoulos, J. Flaskos and A. J. George** 43

Irritability in Panic Disorder: Effects of Imipramine Treatment: **D. J. Nutt and P. Glue** 49

A Short-term Open Trial of Clomipramine in the Treatment of Patients with Panic Attacks: **F. K. Judd, G. D. Burrows, P. F. Marriott, P. Farnbach, S. Blair-West and T. R. Norman** 53

Mouse Strain-dependent Hepatic Interaction of Psychoactive Agents with Ethanol and Biogenic Aldehydes Metabolizing Enzymes: **F. S. Messiha** 61

Case Report

Acute Extrapyramidal Reactions Following Lithium and Sulpiride Co-administration: Two Case Reports: **T. G. Dinan and V. O'Keane** 67

Letters to the Editors

Buprenorphine and Schizophrenia: **S. Groves and D. Nutt** 71

Clomipramine-induced Mania in Obsessive-Compulsive Disorder: **E. Vieta, M. Bernardo and J. Vallejo** 72

Book Reviews

Human Psychopharmacology: Measures and Methods, reviewed by **B. E. Leonard** 75

Biological Perspectives of Schizophrenia, reviewed by **P. F. Lidde** 76

Human Psychopharmcology, reviewed by **J. S. Kerr** 77

Handbook of Clinical Psycho-neuroendocrinology, reviewed by **B. A. Leatherdale** 78

The Suspended Revolution, reviewed by **I. Hindmarch** 78

Issue No. 2 June 1991

Reviews

Antidepressants and Memory: A Review: **P. J. Thompson** 79

Performance Tests in Human Psychopharmacology (2): Content Validity, Criterion Validity, and Face Validity: **A. C. Parrott** 91

Original Articles

Effects of Estazolam and Triazolam on Transient Insomnia Associated with Phase-shifted Sleep: **P. K. Schweitzer, G. Koshorek, M. J. Muehlbach, D. D. Morris, T. Roehrs, J. K. Walsh and T. Roth** 99

Tetrahydroaminoacridine in Alzheimer's Dementia: Clinical and Biochemical Results of a Double-blind Crossover Trial: **A. Åhlin, H. Nybäck, T. Junthe, G. Öhman and I. Nordgren** 109

The Effects of Caffeine on Two Computerized Tests of Attention and Vigilance: **L. J. Frewer and M. Lader** 119

The Effects of Clobazam on Critical Flicker Fusion Threshold and Symptomatology During the Menstrual Cycle: **L. Dye and I. Hindmarch** 129

The Influence of Ageing on Serum Levels of Tertiary Tricyclic Antidepressants: **E. Leinonen and P. Ylitalo** 139

Fengabine in Depression: A Placebo-controlled Study of a GABA Agonist: **E. S. Paykel, A. E. van Woerkom, D. E. Walters, W. White and J. Mercer** 147

ECT-induced Prolactin Release: Effect of Sex, Electrode Placement and Serotonin Uptake Inhibition: **A. P. Zis, A. D. Goumeniouk, C. M. Clark, B. E. K. Grant, R. A. Remick, R. W. Lam and E. J. Garland** 155

The Release of Oxytocin, Vasopressin and Associated Neurophysins After Electroconvulsive Therapy: **A. I. F. Scott, P. A. Shering, S. L. Lightman, J.-J. Legros and L. J. Whalley** 161

Modulation of Mouse Brain Dopamine, Serotonin and Metabolites by Methionine: Implications for Schizophrenia and Genetics: **F. S. Messiha** 165

Book Reviews

Responsibility for Drug-Induced Injury, reviewed by **P. N. Nott** 171

Working Methods in Neuropsychopharmacology: a Team Approach, reviewed by **G. N. Woodruff** .. 172

Dictionary of Pharmacological and Chemical Synonyms, reviewed by **I. Hindmarch** 172

Abstracts

British Sleep Society 2nd Annual Meeting, 24–26 September, 1990. Leeds: Editor, **I. Hindmarch**; Guest Editor, **C. D. Hanning** 173

Issue No. 3 September 1991

Reviews

Increased Anticholinergic Levels, Memory and Judgement: **J. Walkup** 189

Performance Tests in Human Psychopharmacology (3): Construct Validity and Test Interpretation: **A. C. Parrot** 197

Original Articles

Effects of Lormetazepam and other Benzodiazepine Receptor Ligands on Car Driving-related Skills: **H.-P. Willumeit, H. Ott and Chr. Kushel** 209

Effects of Single Doses of Alprazolam and Alcohol Alone and in Combination on Psychological Performance: **A. Bond, J. C. Silveira and M. Lader** 219

Study of Effects of Clobazam and Lorazepam on Memory and Cognitive Functions in Healthy Subjects: **A. Patat, M. J. Klein, A. Surjus, A. Rostand and J. Granier** 229

Is there a Therapeutic Window for Plasma Concentration of Mianserin plus Desmethylmianserin? **K. Otani, S. Kaneko, H. Sasa, T. Kondo and Y. Fukushima** 243

Moclobemide Pharmacokinetics in Depressed Patients: Lack of Age Effect: **K. Maguire, A. Pereira and J. Tiller** 249

The Effect of Acute Alcohol Intoxication on Psychometric Testing and 5-HT-induced Platelet Aggregation in Normal Subjects; Modulatory Role of Evening Primrose Oil: **R. Corbett, J. B. A. Meaghar and B. E. Leonard** 253

Case Report

Neoplasia and the Neuroleptic Malignant Syndrome: **P. W. R. Woodruff, E. Palazidou, I. Cranston, B. K. Toone, B. Summers and A. L. W. F. Eddleston** 257

Letter to Editors

Time-course of the Enzymatic Autoinduction of Carbamazepine: **R. Zanarkowski** 261

Book Reviews

Brain Messengers and the Pituitary, reviewed by **F. J. P. Ebling** 263

Brain Messengers and the Pituitary, reviewed by **B. E. Leonard** 264

Steroids in Diseases of the Central Nervous System, reviewed by **B. E. Leonard** 265

Introduction to Neuropharmacology, reviewed by **B. E. Leonard** 266

Supplement October 1991

SEROTONIN AND BEHAVIOURAL DISTURBANCES

Guest Editors: Berend Olivier, *Solvay-Duphar, The Netherlands*
Brian Leonard, *University of Galway, Ireland*

Clinical Significance of 5-HT Uptake Inhibitors: **S. A. Montgomery** S3

Serotonin and Gambling Dependence: **I. Moreno, J. Saiz-Ruiz and J. J. López-Ibor** S9

The Present and the Future of Serotonergic Drugs: **H. M. Van Praag** S13

5-Hydroxytryptamine and Alcoholism: **L. Ferreira and P. Soares-Da-Silva** S21

Do Panic Attacks Reflect an Abnomality in Serotonin Receptor Subtypes?: **J. A. Den Boer and H. G. M. Westenberg** S25

Serotonin, Impulsivity and Suicide: **M. Bourgeois** S31

Pharmacology of Serotonin Neuronal Systems: **C. A. Fontes Ribeiro** S37

Preclinical Pharmacology of Flesinoxan: A Potential Anxiolytic and Antidepressant Drug: **J. Schipper, M. Th. M. Tulp, B. Berkelmans, J. Mos, J. A. M. Van Der Heijden and B. Olivier** S53

Serotonin Reuptake Blockers: Is There Preclinical Evidence for Their Efficacy in Obsessive-Compulsive Disorder?: **M. Tulp, B. Olivier, J. Schipper, G. Van Der Poel, J. Mos and J. Van Der Heyden** S63

Serotonergic Receptors in Anxiety and Aggression; Evidence from Animal Pharmacology: **B. Olivier, M. Th. M. Tulp and J. Mos** S73

Issue No. 4 December 1991

Original Articles

EEG Mapping Central Effects of Multiple Doses of Linopirine—a Cognitive Enhancer—in Healthy Elderly Male Subjects: **B. Saletu, A. Darragh, H. P. Breuel, W. Herrmann, P. Salmon, R. Coen and P. Anderer** 267

Interactions of Smoking and Lunch with Effects of Caffeine on Cardiovascular Functions and Information Processing: **M. Hasenfratz, F. Jaquet, D. Aeschbach and K. Bättig** 277

Effects of Acute and Repeated Doses of Two Muscle Relaxants, Chlormezanone and Thiocolchicoside, on Vigilance and Psychomotor Performance of Healthy Volunteers: **A. Patat, M. J. Klein, A. Surjus, M. Renault, Y. Rezvani and J. Granier** ... 285

A Pharmacodynamic Study of Quazepam and Triazolam: **G. Casucci, A. di Costanzo, R. Riva, S. Allocca and G. Tedeschi** ... 293

Effects of Alcohol on Serum Fluphenazine Levels in Stable Chronic Schizophrenics: **S. D. Soni, J. S. Bamrah and J. Krska** ... 301

Nocturnal and Next-day Effects of Ethanol and Basal Level of Sleepiness: **T. Roehrs, J. Yoon and T. Roth** ... 307

The Comparative Psychopharmacology of 5HT Reuptake Inhibitors: **J. S. Kerr, N. Sherwood and I. Hindmarch** ... 313

Amphetamine Effects on Recovery Sleep Following Total Sleep Deprivation: **D. M. Penetar, H. C. Sing, D. R. Thorne, M. L. Thomas, J. B. Fertig, A. S. D. Schelling, J. C. Sealock, P. A. Newhouse and G. Belenky** ... 319

Comment
What do 5HT Re-uptake Inhibitors do in Obsessive-Compulsive Disorders?: **D. Healy** ... 325

Case Report
Antidepressant Induced Suicidal Ideation: **W. Creaney, I. Murray and D. Healy** ... 329

Book Reviews
The NMDA Receptor: Reviewed by **B. E. Leonard** ... 333

The Perception and Management of Drug Safety Risks: Reviewed by **P. D. Stonier** ... 334

Advances in Learning and Behavioural Disabilities, Supplement 1, 1986. Methodological Issues in Human Psychopharmacology: Reviewed by **B. J. Sahakian** ... 335

Side Effects of Drugs Annual 14, 1990: Reviewed by **J. A. Sutton** ... 335

The Biology of Nicotine Dependence: Reviewed by **N. Sherwood** ... 336

Author Index ... 337

Keyword Index ... 338